Repare Therapeutics (NASDAQ:RPTX) Stock Rating Reaffirmed by HC Wainwright

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 196.74% from the stock’s current price.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Repare Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.33.

Repare Therapeutics Price Performance

Shares of Repare Therapeutics stock opened at $3.37 on Monday. The stock has a market cap of $143.04 million, a price-to-earnings ratio of -3.06 and a beta of 0.71. The firm’s 50-day moving average is $3.26 and its two-hundred day moving average is $3.61. Repare Therapeutics has a 1 year low of $2.71 and a 1 year high of $13.17.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.03. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. On average, equities analysts expect that Repare Therapeutics will post -2.15 earnings per share for the current year.

Hedge Funds Weigh In On Repare Therapeutics

A number of large investors have recently made changes to their positions in the business. BVF Inc. IL boosted its position in shares of Repare Therapeutics by 24.6% in the 4th quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock worth $75,435,000 after purchasing an additional 2,041,612 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Repare Therapeutics by 212.1% in the second quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after acquiring an additional 284,036 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth about $289,000. Marshall Wace LLP acquired a new position in shares of Repare Therapeutics during the second quarter valued at about $273,000. Finally, Bank of Montreal Can raised its position in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after purchasing an additional 5,673 shares during the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.